• No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia
• Company plans to export PCV13 vaccine components
• "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development."

SEONGNAM, South Korea, May 21, 2025 /PRN...